Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on September 28, 2026

Sep. 28, 2026

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Indeterminate GlobeNewswire

Sep. 28, 2026

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Indeterminate GlobeNewswire

Sep. 28, 2026

BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team

Indeterminate GlobeNewswire

Sep. 28, 2026

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Indeterminate GlobeNewswire

Sep. 28, 2026

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Indeterminate GlobeNewswire

Sep. 28, 2026

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

Indeterminate GlobeNewswire

Sep. 28, 2026

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

Indeterminate GlobeNewswire

Sep. 28, 2026

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

Indeterminate GlobeNewswire

Sep. 28, 2026

NOTICE TO DISREGARD -- Direct Meds

Indeterminate GlobeNewswire

Sep. 28, 2026

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Indeterminate GlobeNewswire

Sep. 28, 2026

Flyte Named Official Air Travel Partner of the 34th Annual Hamptons International Film Festival

Indeterminate GlobeNewswire

Sep. 28, 2026

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Indeterminate GlobeNewswire

Sep. 28, 2026

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

Indeterminate GlobeNewswire

Sep. 28, 2026

LULU Investor Investigation: Lululemon Under Investigation for Securities Fraud on behalf of Investors with Losses – Contact BFA Law

Indeterminate GlobeNewswire

Sep. 28, 2026

Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors

Indeterminate GlobeNewswire

Sep. 28, 2026

Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno

Indeterminate GlobeNewswire

Sep. 28, 2026

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition

Indeterminate GlobeNewswire

Sep. 28, 2026

Vocalbeats.AI Supports FutureChina Global Forum 2026 and Advances Practical AI Innovation

Indeterminate GlobeNewswire

Sep. 28, 2026

Alex Bodi and Prof. Dr Dieter Lazik sign a contract for ALPHA WHEY and BODI Energy Drink

Indeterminate GlobeNewswire

Sep. 28, 2026

Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire